Suppr超能文献

CC趋化因子配体18通过激活肾移植患者的PI3K/mTOR信号通路促进尿路上皮癌的细胞增殖和转移。

CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.

作者信息

Bo Song, Donghao Shang, Guangqi Kong, Ye Tian

机构信息

Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Department of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.

出版信息

Urol Int. 2018;101(4):450-458. doi: 10.1159/000492180. Epub 2018 Sep 6.

Abstract

OBJECTIVE

The study aimed to investigate the role of chemokine (C-C motif) ligand 18 (CCL18) in the progression of urothelial carcinoma (UC) after renal transplants (RT).

METHODS

Tissues were collected from 60 patients with UC in which 24 were after RT. The tissues were all obtained from patients after radical cystectomy. Expression levels of CCL18 were examined by immunohistochemistry, RT-polymerase chain -reaction (RT-PCR), and quantitative RT-PCR, respectively. WST-1 assay was performed to determine proliferative capacity of UC cells. Migration and invasion of UC cells were analyzed by the using of chemotaxis and Transwell system. Western blotting was applied to assess the activation of PI3K-mTOR (Mammalian Target of Rapamycin) signaling.

RESULTS

Compared to normal urothelial tissues, the expression levels of CCL18 were significantly increased in tumors of UC, and even more in tumors of UC after RT. Ectopic expression of CCL18 efficiently enhanced the proliferation of UC cells and moreover, exacerbated the migration and invasion of UC cells. Furthermore, overexpressed CCL18 increased the phosphorylation of PI3K, Akt, and mTOR in UC cells, suggesting the hyperactivation of PI3K/Akt/mTOR signaling.

CONCLUSIONS

The results demonstrate the critical role of CCL18 in the progression of UC, especially in receipt with RT. Our study indicates that CCL18 could serve as a biomarker and therapeutic target in diagnosis of recipients with UC after RT.

摘要

目的

本研究旨在探讨趋化因子(C-C基序)配体18(CCL18)在肾移植(RT)后尿路上皮癌(UC)进展中的作用。

方法

收集60例UC患者的组织,其中24例为RT后患者。所有组织均取自根治性膀胱切除术后的患者。分别采用免疫组织化学、逆转录聚合酶链反应(RT-PCR)和定量RT-PCR检测CCL18的表达水平。采用WST-1法检测UC细胞的增殖能力。利用趋化性和Transwell系统分析UC细胞的迁移和侵袭能力。应用蛋白质免疫印迹法评估PI3K-雷帕霉素靶蛋白(mTOR)信号通路的激活情况。

结果

与正常尿路上皮组织相比,UC肿瘤中CCL18的表达水平显著升高,RT后UC肿瘤中的表达水平更高。CCL18的异位表达有效增强了UC细胞的增殖,此外,还加剧了UC细胞的迁移和侵袭。此外,过表达的CCL18增加了UC细胞中PI3K、Akt和mTOR的磷酸化水平,提示PI3K/Akt/mTOR信号通路过度激活。

结论

结果表明CCL18在UC进展中起关键作用,尤其是在RT患者中。我们的研究表明,CCL18可作为RT后UC患者诊断的生物标志物和治疗靶点。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验